# COPERNICUS (NCT06667076)

> A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06667076
- Phase: PHASE2
- Status: RECRUITING
- Sponsor: Janssen Research & Development, LLC
- Conditions: Carcinoma, Non-Small-Cell Lung
- Interventions: Amivantamab; Lazertinib; Chemotherapy: Pemetrexed; Chemotherapy: Carboplatin
- Enrollment: 480
- Primary outcome: Progression Free Survival (PFS)

## Commentary we found

- X threads: 4

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=copernicus-nct06667076